Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: Outcome of anticoagulation

Digestive Diseases and Sciences

Volumn 58, Issue 6, 2013, Pages 1776-1780

  Werner, K T ^a   Sando, Shawna ^a   Carey, Elizabeth J ^a   Vargas, Hugo E ^a   Byrne, Thomas J ^a   Douglas, David D ^a   Harrison, M E ^a   Rakela, Jorge ^a   Aqel, Bashar A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anticoagulation therapy; Hypercoagulable disorders; Liver cirrhosis; Liver transplant; Portal vein thrombosis (PVT)

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; END STAGE LIVER DISEASE; ESOPHAGUS VARICES; FEMALE; HEMOCHROMATOSIS; HEPATITIS C; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VASCULAR PATENCY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; END STAGE LIVER DISEASE; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PORTAL VEIN; PREVALENCE; RETROSPECTIVE STUDIES; THROMBOPHILIA; TREATMENT OUTCOME; VENOUS THROMBOSIS; WAITING LISTS; WARFARIN;

EID: 84879503103     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2548-y     Document Type: Article

References (28)

1. Primignani M. Portal vein thrombosis, revisited. Dig Liver Dis. 2009;42:163-170.
2. Aqel B. Vascular diseases of the liver. In: Talley N, Lindor KD, Vargas HE, eds. Liver and Biliary Disease. Oxford: Wiley-Blackwell; 2010:267-273.
3. Julapalli VR, Bray PF, Duchini A. Elevated factor VIII and portal vein thrombosis. Dig Dis Sci. 2003;48:2369-2371.
4. Rodriguez-Luna H, Vargas HE. Portal vein thrombosis. Current Treat Options Gastroenterol. 2007;10:435-443.
5. Northup PG, Sundaram V, Fallon MB, et al. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost. 2008;6:2-9.
6. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;21:1238-1247.
7. Amitrano L, Guardascione MA, Ames PR. Coagulation abnormalities in cirrhotic patients with portal vein thrombosis. Clin Lab. 2007;53:583-589.
8. Cho JY, Suh KS, Shin WY, Lee HW, Yi NJ, Lee KU. Thrombosis confined to the portal vein is not a contraindication for living donor liver transplantation. World J Surg. 2008;32:1731-1737.
9. Englesbe MJ, Kubus J, Muhammad W, et al. Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl. 2010;16:83-90.
10. Karatzas T, Lykaki-Karatzas E, Demirbas A, et al. Management of portal vein thrombosis in liver transplantation. Transpl Proc. 1997;29:2866-2867.
11. Joh JH, Kim DI. Mesenteric and portal vein thrombosis: treated with early initiation of anticoagulation. Eur J Vasc Endovasc Surg. 2005;29:204-208.
12. Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004;40:736-741.
13. Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology. 2000;31:345-348.
14. Mangia A, Margaglione M, Cascavilla I, et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol. 1999;94:2983-2987.
15. Romero Gomez M, Suarez Garcia E, Lopez Lacomba D, Marchante I, Grande L, Castro Fernandez M. Antiphospholipid antibodies are related to portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2000;31:237-240.
16. Martinelli I, Primignani M, Aghemo A, et al. High levels of factor VIII and risk of extra-hepatic portal vein obstruction. J Hepatol. 2009;50:916-922.
17. Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology. 2009;137:2105-2111.
18. Condat B, Pessione F, Helene Denninger M, Hillaire S, Valla D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology. 2000;32:466-470.
19. Condat B, Pessione F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology. 2001;120:490-497.
20. Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54:691-697.
21. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
22. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009;49:1729-1764.
23. Englesbe MJ, Schaubel DE, Cai S, Guidinger MK, Merion RM. Portal vein thrombosis and liver transplant survival benefit. Liver Transpl. 2010;16:999-1005.
24. Blum U, Haag K, Rossle M, et al. Noncavernomatous portal vein thrombosis in hepatic cirrhosis: treatment with transjugular intrahepatic portosystemic shunt and local thrombolysis. Radiology. 1995;195:153-157.
25. Radosevich PM, Ring EJ, LaBerge JM, et al. Transjugular intrahepatic portosystemic shunts in patients with portal vein occlusion. Radiology. 1993;186:523-527.
26. Luca A, Miraglia R, Caruso S, et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut. 2011;60:846-852.
27. Senzolo M, Ferronato C, Burra P, Sartori MT. Anticoagulation for portal vein thrombosis in cirrhotic patients should be always considered. Intern Emerg Med. 2009;4:161-162; author reply 3-4.
28. Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2009;44:448-451.